NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 208 filers reported holding NEKTAR THERAPEUTICS in Q3 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $3,176,000 | +29.3% | 52,099 | +3.5% | 0.06% | +28.3% |
| Q2 2018 | $2,457,000 | -75.3% | 50,322 | -46.2% | 0.05% | -76.2% |
| Q1 2018 | $9,931,000 | -40.8% | 93,459 | -66.7% | 0.19% | -35.9% |
| Q4 2017 | $16,773,000 | +91.6% | 280,868 | -23.0% | 0.30% | +90.5% |
| Q3 2017 | $8,754,000 | – | 364,756 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |